Original ArticleOpen Access

Time in Therapeutic Range (TTR) and the Efficacy of Anticoagulant Therapy in Preventing Thromboembolism in Cardiac Patients Receiving Warfarin at Shifa Medical Complex: A Cross-Sectional Study

DOI: 10.23958/ijirms/vol06-i10/1265· Pages: 739 - 744· Vol. 6, No. 10, (2021)· Published: October 29, 2021
PDF
Views: 1,167 PDF downloads: 202

Abstract

Background: Anticoagulant control is assessed by Time in Therapeutic Range (TTR). For a given patient, TTR is defined as the duration of time in which the patient’s International Normalized Ratio (INR) values were within a desired range. Aim: To assess TTR in patients receiving anticoagulant treatment and the efficacy of Anticoagulant therapy in preventing Thromboembolism in Cardiac Patients receiving Warfarin for atrial fibrillation and with high CHADS VASC score, valvular and non-valvular heart disease at a referral center for cardiovascular diseases at Gaza Shifa Medical Complex, Palestine. Materials and Method: Over 8 months, we enrolled eligible patients presenting to Shifa Medical Complex in Gaza for regular INR testing. Demographic data, medical history, and current medications were determined for all participants. TTR was assessed by both tradition and cross-sectional methods. Results: A total of 46 patients (mean age 57.15±12.6 years, 50% women) underwent 230 INR measurements. The mean TTR was calculated as 50.86±21.37%. Participants of this study were assessed for their risk of having stroke using CHADS VASC score and risk of bleeding using HAS BLED score. Risk of stroke was significantly higher for females (P= 0.031). Of the sample patients, 47.8% were in the good control category (TTR >60%), and 52.2% were in the poor control category (TTR <60%). The mean TTR of the studied patients (54.9%) was below the good control range.There were 12 participants had thromboembolism of patients with low traditional TTR. This was statistically significant, TTR with occurrence of thromboembolism, (P= 0.001). Conclusion: We found a mean TTR of 50.86% among study patients diagnosed with atrial fibrillation and high CHADS VASC score, valvular and non - valvular heart disease who were receiving warfarin therapy. None of the risk factor was significantly related to low TTR values among study participants. The study showed the low TTR was associated with increased risk of thromboembolism among participants in this study. Moreover, showed the superiority of tradition TTR over cross-sectional TTR in evaluating anticoagulant therapy.

Keywords

AnticoagulantTime in Therapeutic RangeInternational Normalized RatioCardiac DiseaseGazaPalestine

References

  1. Caldeira D, Cruz I, Morgado G, Stuart B, Gomes C, Martins C, et al. Evaluation of time in therapeutic range in anticoagulated patients:a single-center, retrospective, observational study. BMC Res Notes. 2014;7:891.Google Scholar ↗
  2. Wigle P, Hein B, Bloomfield HE, Tubb M, Doherty M. Updated guidelines on outpatient anticoagulation. Am Fam Physician. 2013;87:556–566.Google Scholar ↗
  3. Zhu J, Alexander GC, Nazarian S, Segal JB, Wu AW. Trends and variation in oral anticoagulant choice in patients with atrial fibrillation 2010-2017. Pharmacotherapy. 2018;38:907–920.Google Scholar ↗
  4. Hirsh J, Fuster V, Ansell J, Halperin JL. American heart association/American college of cardiology foundation guide to warfarin therapy. Circulation. 2013;107:1692–1711.Google Scholar ↗
  5. Gateman D, Trojnar ME, Agarwal G. Time in therapeutic range:warfarin anticoagulation for atrial fibrillation in a community-based practice. Can Fam Physician. 2017;63:e425–e431.Google Scholar ↗
  6. Farsad BF, Abbasinazari M, Dabagh A, Bakshandeh H. Evaluation of time in therapeutic range (TTR) in patients with non-valvular atrial fibrillation receiving treatment with warfarin in Tehran, Iran:a cross-sectional study. J Clin Diagn Res. 2016;10:FC04–FC06.Google Scholar ↗
  7. Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation:CHEST guideline and expert panel report. Chest. 2018;154:1121–1201.Google Scholar ↗
  8. Rosenstein R, Parra D. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(24):2334–5.Google Scholar ↗
  9. Meyer BJ. Time in therapeutic range for warfarin—a European success story. J Watch Cardiol. 2011 Oct 19; Available from: www.jwatch.org/jc201110190000001/2011/10/19/time-therapeutic-range-warfarin-european-success. Accessed 2021Oct19.Google Scholar ↗
  10. Van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control. Chest. 2016;129(5):1155–66.Google Scholar ↗
  11. Connolly S, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2018;118(20):2029–37.Google Scholar ↗
  12. Razouki Z, Ozonoff A, Zhao S, Rose A. Pathways to poor anticoagulation control. J Thromb Haemost. 2014;12(5):628–34.Google Scholar ↗
  13. Rose AJ, Miller DR, Ozonoff A, Berlowitz DR, Ash AS, Zhao S, et al. Gaps in monitoring during oral anticoagulation: insights into care transitions, monitoring barriers, and medication nonadherence. Chest. 2012;143(3):751–7.Google Scholar ↗
  14. Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, et al. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood. 2019;114(5):952–6.Google Scholar ↗
  15. Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA) J Thromb Haemost. 2010;8(10):2182–91.Google Scholar ↗
  16. Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT R score. Chest. 2013;144(5):1555–63.Google Scholar ↗
  17. Kimmel SE, Chen Z, Price M, Parker CS, Metlay JP, Christie JD, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) study. Arch Intern Med. 2017;167(3):229–35.Google Scholar ↗
  18. Obamiro KO, Chalmers L, Bereznicki LR. A Summary of the literature evaluating adherence and persistence with oral anticoagulants in atrial fibrillation. Am J Cardiovasc Drugs. 2016 Jun 4.Google Scholar ↗
  19. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011;106:968–77.Google Scholar ↗
  20. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2018;1:84–91.Google Scholar ↗
  21. Cotté FE, Benhaddi H, Duprat-Lomon I, Doble A, Marchant N, et al. Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries. Clin Ther. 2014;1(36):1160–68.Google Scholar ↗
  22. Mark L, Dani G, Vendrey R, Paragh G, Katona A. Oral anticoagulant therapy and bleeding events with vitamin K antagonists in patients with atrial fibrillation in a Hungarian county hospital. Med Sci Monit. 2015;17:518–25.Google Scholar ↗
  23. Zubaid M, Saad H, Ridha M, Mohanan Nair KK, Rashed W, Alhamdan R, et al. Quality of anticoagulation with warfarin across Kuwait. Hellenic J Cardiol. 2013;54:102–06.Google Scholar ↗
  24. Tan GM, Wu E, Lam YY, Yan BP. Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics. 2010;11:439–48.Google Scholar ↗
  25. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011;31:326–43.Google Scholar ↗
  26. Aghajani MH, Sistanizad M, Abbasinazari M, Ghamsari MA, Ayazkhoo L, Saf O, et al. Potential drug-drug interactions in post-CCU of a teaching hospital. Iranian Journal of Pharmaceutical Research. 2013;12:243–48.Google Scholar ↗
  27. Melamed OC, Horowitz G, Elhayany A, Vinker S. Quality of anticoagulation control among patients with atrial fibrillation. Am J Manag Care. 2011;17:232–37.Google Scholar ↗
  28. Zullig LL, Stechuchak KM, Goldstein KM, Olsen MK, McCant FM, Danus S, et al. Patient-reported medication adherence barriers among patients with cardiovascular risk factors. J Manag Care Spec Pharm. 2015;21:479–85.Google Scholar ↗
Author details